Arranta Bio Signs Contract With MIT to Develop Rapid Manufacturing of mRNA Therapeutics

Arranta Bio, part of Recipharm’s biologics business, has recently signed a contract with MIT to develop a continuous manufacturing technology for mRNA therapeutics. The contract is part of the FDA’s initiative to have a fully integrated, continuous manufacturing production line for mRNA vaccines, which the agency is funding through a contract to MIT – one of the largest awards from the FDA’s CBER office. Enabling rapid manufacturing capacity will provide faster readiness and reaction to new pandemic threats.

The 3-year project will accelerate the deployment not only of mRNA vaccines for rapid response against future pandemics but also of novel mRNA therapeutics to patients around the world. mRNA therapeutics are being researched to support the fight against rare, diseases, infectious viruses (influenza, Zika), and cancers.

The project will address current challenges in the continuous manufacturing of mRNA therapeutics: under the terms of the agreement, the FDA will directly support and inform the advances to enable Arranta Bio and MIT to push the boundaries of current manufacturing and testing processes.

Marc Funk, CEO, Recipharm, said “We are proud to be working with MIT on this ground-breaking FDA initiative to be forward thinkers and push the boundaries of biologics manufacturing. Our work can enable new vaccines and therapies to be deployed quickly and be economically viable for patients in need. This project is yet another step towards our vision to be the CDMO of choice, for the benefit of patients.”

Richard D. Braatz, Center Director at MIT, said “This project leverages advances made at MIT in the continuous pharmaceutical manufacturing made over the last 10+ years, as well as more recent advances in the modular manufacturing of vaccines and other biotherapeutics. MIT is pleased to collaborate with Arranta Bio and researchers at Rensselaer Polytechnic Institute and Pennsylvania State University to advance technologies for continuous mRNA manufacturing.”

Recipharm continues to build its presence in the biologics market, following the acquisitions of Arranta Bio, Vibalogics and GenIbet in 2022.

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical and biopharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical and biologics product development, and development and manufacturing of medical devices. Recipharm manufactures several hundred different products for customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. For more information, visit www.recipharm.com.